Search results
US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition
FOX 4 Kansas City· 1 day agoWASHINGTON (AP) — Federal regulators are challenging patents on 20 brand-name drugs, including the...
FTC challenges ‘bogus’ patents on Ozempic, other drugs that ‘block competition’
Market Watch· 1 day agoFederal regulators are challenging patents on 20 brand-name drugs, including the blockbuster...
Gold Gains as Fed’s Rate Comments Are Less Hawkish Than Feared
Bloomberg via Yahoo Finance· 7 hours agoMeant to Reshape Middle EastTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests...
US, Europe Fear of China's Dominance Threatens Climate Fight, Says Xi's Envoy
Bloomberg via Yahoo Finance· 4 hours ago...from BloombergUS and Saudis Near Defense Pact Meant to Reshape Middle EastTesla Axes Supercharger...
Gas Prices Are Putting Washington’s Boldest Climate Policy at Risk
Bloomberg via Yahoo Finance· 17 hours ago...repealing Washington state’s most ambitious climate policy: a cap-and-trade program.Most Read...
US challenges 'bogus' patents on Ozempic, other drugs in effort to spur competition
Pittsburgh Tribune-Review· 1 day agoFederal regulators are challenging patents on 20 brand-name drugs, including the blockbuster...
Sanders launches Senate investigation into ‘outrageously high’ pricing of Ozempic, Wegovy
CNN via Yahoo News· 6 days agoIt spent $4.6 billion on Ozempic in 2022, compared with $2.6 billion the year before, according to...
Sen. Sanders investigates high cost of obesity drugs Ozempic and Wegovy
WCAX-TV Vermont· 5 days agoVermont Senator Bernie Sanders this week launched an investigation into the pricing of Ozempic and...
Cheaper Chicken Gives Pilgrim’s a Boost as Demand Rebounds
Bloomberg via Yahoo Finance· 6 hours agoMeant to Reshape Middle EastTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests...
FTC cracks down on drugmaker patents, including Novo's Ozempic; analysts weigh in
Investing.com· 2 days agoFTC cracks down on drugmaker patents, including Novo's Ozempic; analysts weigh in